PLA2G7 and cardiovascular disorder: One of the main challenges in targeting PLA2G7 with small-molecule inhibitors like darapladib is their short half-life (~30 h) [42], which necessitates frequent dosing and may limit their long-term efficacy in cardiovascular disease and cancer therapy [41].